Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia

Abstract Prostate-specific antigen (PSA) screening for prostate cancer (PCa) is limited by the lack of specificity but is further complicated in the benign prostatic hyperplasia (BPH) population which also exhibit elevated PSA, representing a clear unmet need to distinguish BPH from PCa. Herein, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Michael A. Kiebish, Poornima Tekumalla, Shobha Ravipaty, Albert Dobi, Shiv Srivastava, Wenfang Wu, Saurabh Patil, Tracey Friss, Allison Klotz, Alagarsamy Srinivasan, Jennifer Cullen, Inger L. Rosner, Amina Ali, Sandra Laszlo, Michele Petrovic, Neil Fleshner, Jeonifer Garren, Greg Miller, Nischal Mahaveer Chand, Leonardo O. Rodrigues, Elder Granger, Mark D. Kellogg, Shen Luan, Eleftherios Diamandis, Viatcheslav R. Akmaev, Rangaprasad Sarangarajan, Chas Bountra, Stephen J. Freedland, David G. McLeod, Niven R. Narain
Format: article
Language:EN
Published: Nature Portfolio 2021
Subjects:
Medicine
R
Science
Q
Online Access:https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e51
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/30b5d2f52b594d5593705963e0ea8e51

Similar Items